このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
SPPI 株式概要
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Spectrum Pharmaceuticals, Inc. 競合他社
価格と性能
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.03 |
| 52 Week High | US$1.57 |
| 52 Week Low | US$0.32 |
| Beta | 2.14 |
| 1 Month Change | 4.54% |
| 3 Month Change | -1.90% |
| 1 Year Change | 17.05% |
| 3 Year Change | -71.39% |
| 5 Year Change | -95.10% |
| Change since IPO | -99.25% |
最新ニュース
Recent updates
Analysts Just Made A Huge Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Forecasts
May 14
Earnings Update: Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Just Reported And Analysts Are Boosting Their Estimates
May 12Spectrum plunges 28% after FDA scientists question poziotinib evidence for NSCLC
Sep 20Is Spectrum Pharmaceuticals (NASDAQ:SPPI) In A Good Position To Invest In Growth?
Sep 16Spectrum Pharmaceuticals stock jumps 10% afterhours on FDA nod for Rolvedon injection
Sep 09Spectrum Pharmaceuticals: Revisiting This 'Soap Opera'
Aug 21Spectrum Pharmaceuticals Q2 2022 Earnings Preview
Aug 10Here's Why We're A Bit Worried About Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Jun 04Spectrum Pharmaceuticals: Some Last Words
Feb 25Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
Oct 05Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
Aug 12Spectrum's Big Approval: Any Day Now
Jul 29FDA initiates pre-approval inspection for Spectrum pharmaceuticals' ROLONTIS
Jun 01Here's Why We're Watching Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Situation
May 31We're Keeping An Eye On Spectrum Pharmaceuticals' (NASDAQ:SPPI) Cash Burn Rate
Feb 12Spectrum Pharma drops after announcing less-than-favorable Phase 2 data
Dec 22Here's What Spectrum Pharmaceuticals, Inc.'s (NASDAQ:SPPI) Shareholder Ownership Structure Looks Like
Dec 21Spectrum Pharma Is Down But Not Out
Nov 16Spectrum Shareholders In Limbo As FDA Delays Rolontis Decision Date, Agrees To Discuss Poziotinib
Nov 11株主還元
| SPPI | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 5.3% | -2.0% | 1.6% |
| 1Y | 17.0% | 5.4% | 21.5% |
業界別リターン: SPPI過去 1 年間で7.1 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: SPPI過去 1 年間で20.8 % の収益を上げたUS市場を上回りました。
価格変動
| SPPI volatility | |
|---|---|
| SPPI Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: SPPIの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: SPPIの 週次ボラティリティ は、過去 1 年間で15%から7%に減少しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1987 | 86 | Tom Riga | www.sppirx.com |
Spectrum Pharmaceuticals, Inc. 基礎のまとめ
| SPPI 基礎統計学 | |
|---|---|
| 時価総額 | US$209.89m |
| 収益（TTM） | -US$67.71m |
| 売上高(TTM) | US$25.73m |
8.2x
P/Sレシオ-3.1x
PER（株価収益率SPPI は割高か？
公正価値と評価分析を参照収益と収入
| SPPI 損益計算書（TTM） | |
|---|---|
| 収益 | US$25.73m |
| 売上原価 | US$2.86m |
| 売上総利益 | US$22.87m |
| その他の費用 | US$90.58m |
| 収益 | -US$67.71m |
直近の収益報告
Mar 31, 2023
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.33 |
| グロス・マージン | 88.90% |
| 純利益率 | -263.16% |
| 有利子負債／自己資本比率 | 107.6% |
SPPI の長期的なパフォーマンスは？
過去の実績と比較を見る